Kim et al. (2019) evaluated the outcomes of 30 patients with R/R NHL treated with pembrolizumab, including 14 presenting with EBV-positive ENKTL. The ORR was 44%, five patients achieved CR, and one achieved PR. Patients with ENKTL with high PD-L1 expression in tumor cells (PD-L1-positive staining >50%) had a higher response rate than those with low PD-L1 expression (67% vs. 20%). The gene discussed is CD274; the disease is non-Hodgkin lymphoma.